Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

G. Chen(Harbin Medical University), Changxuan You(Southern Medical University), C. Wang(Tianjin Medical University Cancer Institute and Hospital), Shengxiang Ren(Tongji University), Lin Chen(Shantou University), Sheng Lu(Shanghai Jiao Tong University), J. Wang(Peking University), Y. Zhang(Zhejiang Cancer Hospital), Yi Luo(Kunming Institute of Botany), M. Ye(Shanghai Jiao Tong University), Chengping Hu(Central South University), L. Zhang(Sun Yat-sen University), W. F. Mader(Harbin Institute of Petroleum), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Jianan Huang(Soochow University), Songwen Zhou(Tongji University), S. Zhang(Capital Medical University), J. Feng(Hangzhou First People's Hospital), Xuetong Liu(Academy of Military Medical Sciences), Caicun Zhou(Tongji University), Qingyu Xiu(Second Military Medical University), L. Zhang(University of Manchester)
Annals of Oncology
March 2, 2013
10.1093/annonc/mdt012
Cited by 120

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k